secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viatris Inc (VTRS)
CIK:        0001792044
Form:       8-K
Filed at:   2026-08-06T11:56:03+00:00
Accession:  0001792044-26-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viatris Q2 2026: Revenue $3.8B (+5%), GAAP net loss $119M, raises full-year guidance
--------------------------------------------------------------------------------

- Total revenues $3.8B, up 5% reported and 3.5% operationally vs Q2 2025; GAAP net loss $119M.
- Adjusted EBITDA $1.2B, up 8% operationally; gross leverage ratio reduced to 2.9x.
- Raised 2026 financial guidance midpoints for all metrics; expects balanced H2.
- Returned ~$550M to shareholders including ~$270M share repurchases through early August.
- Pipeline milestones: U.S. FDA approval of Gwyn Lo; sale of global rights to Tyrvaya.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/0001792044-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/vtrs-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001792044-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer